Get started
Author

Steven Chuan-Hao Kao

Observed names: S. C. Kao, S. C.‐H. Kao, S. Kao, S.C. Kao, Steven C Kao, Steven C. Kao, Steven C.H. Kao, Steven Kao
Observed institutions: Camden and Campbelltown Hospitals, The University of Sydney, Royal Prince Alfred Hospital, Concord Repatriation General Hospital, Liverpool Hospital, Chris O’Brien Lifehouse, Asbestos Diseases Research Institute, Sydney Local Health District
OpenAlex ID: A5110209017
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
2017 · Nico van Zandwijk, Nick Pavlakis, et al. · The Lancet Oncology · 727
Use of chemotherapy at end of life in oncology patients
2009 · S. Kao, J. Shafiq, et al. · Annals of Oncology · 161
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
2013 · Douglas W Henderson, Glen Reid, et al. · Journal of Clinical Pathology · 126
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
2011 · Steven Chuan-Hao Kao, Sonja Klebe, et al. · Journal of Thoracic Oncology · 91
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study
2022 · Aurelien Marabelle, Philippe A Cassier, et al. · The Lancet. Gastroenterology & hepatology · 85
How long is too long? A scoping review of health system delays in lung cancer
2018 · Ashanya Malalasekera, Sharon Nahm, et al. · European Respiratory Review · 81
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
2024 · A.R. Filippi, J. Bar, et al. · ESMO Open · 69
PDF
Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy
2018 · David Levy, Haryana M. Dhillon, et al. · Supportive Care in Cancer · 68
Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma
2011 · Steven Chuan-Hao Kao, Tristan D. Yan, et al. · Journal of Thoracic Oncology · 65
PDF
Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
2025 · Tony S. K. Mok, Helena Alexandra Yu, et al. · Journal of Clinical Oncology · 56
A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability
2018 · Judith Lacey, Anna J. Lomax, et al. · Supportive Care in Cancer · 45
A survey of patient and caregiver experience with malignant pleural mesothelioma
2019 · Anne Warby, Haryana M. Dhillon, et al. · Supportive Care in Cancer · 42
Malignant mesothelioma
2010 · S. C.‐H. Kao, G. Reid, et al. · Internal Medicine Journal · 38
The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment
2022 · Anna E.B. McLean, Steven C. Kao, et al. · Lung Cancer · 37
MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
2021 · B.C. Cho, R.C. Doebele, et al. · Journal of Thoracic Oncology · 36
PDF
Biomarkers in malignant pleural mesothelioma: current status and future directions
2018 · Tamkin Ahmadzada, Glen Reid, et al. · Journal of Thoracic Disease · 31
PDF
A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma
2016 · Steven C Kao, Michaela B Kirschner, et al. · British Journal of Cancer · 25
PDF
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
2020 · Tamkin Ahmadzada, Wendy A. Cooper, et al. · JTO Clinical and Research Reports · 24
Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma
2020 · Alexander Davis, Annabelle Mahar, et al. · Clinical Lung Cancer · 20
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
2025 · Adel Shahnam, Alexander Davis, et al. · Lung Cancer · 18
Times to Diagnosis and Treatment of Lung Cancer in New South Wales, Australia: A Multicenter, Medicare Data Linkage Study
2018 · Ashanya Malalasekera, Prunella L. Blinman, et al. · Journal of Oncology Practice · 17
Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer
2024 · Samuel Stevens, Udit Nindra, et al. · Journal of Geriatric Oncology · 16
PDF
Elevated neutrophil‐to‐lymphocyte ratio ( NLR ) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab
2022 · Udit Nindra, Adel Shahnam, et al. · Thoracic Cancer · 16
PDF
Patterns of care for malignant pleural mesothelioma patients compensated by the D ust D iseases B oard in N ew S outh W ales, A ustralia
2012 · S. C.‐H. Kao, S. Clarke, et al. · Internal Medicine Journal · 16
Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
2018 · Alice T. Shaw, Jean-François Martini, et al. · Cancer Research · 14
Works count: 61
Citation count: 2,067
H-index: 19
I10-index: 30
Year
Topic
Type